Brief: Gamida Cell's Therapy In Blood Cancer Treatment Receives FDA Approval
17/04/2023 21:21
April 17 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL’S ALLOGENEIC CELL THERAPY OMISIRGE®
(OMIDUBICEL-ONLV) RECEIVES FDA APPROVAL
Source text for Eikon: ID:nBw6QtNrFa
Further company coverage: GMDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq